PMID- 24985882
OWN - NLM
STAT- MEDLINE
DCOM- 20150514
LR  - 20211021
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 31
IP  - 8
DP  - 2014 Aug
TI  - How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients 
      with chronic lymphocytic leukemia, maintenance rituximab or observation.
PG  - 104
LID - 10.1007/s12032-014-0104-7 [doi]
AB  - The open-label, prospective, observational study aimed to evaluate whether the 
      addition of maintenance rituximab (MR) improved progression-free survival (PFS) 
      and overall survival (OS), after fludarabine, cyclophosphamide, and rituximab 
      (FCR) for cytogenetic risk-tailored elderly patients with chronic lymphocytic 
      leukemia (CLL). Enrolled 201 patients (ages 65-84 years) who received FCR and 
      gained an overall response. One hundred and four of 201 patients were in the 
      observation (OBS) arm while 97/201 patients continued to receive MR therapy. 
      After FCR, no more benefits were provided by MR versus OBS in cytogenetic better 
      intermediate-risk cohort. PFS at 10 years reached 68.6 versus 58.1 % (P > 0.05). 
      Ten-year OS was 81.8 versus 74.6 % (P > 0.05). However, the improvement of PFS 
      and OS were as dramatic as the improvements of being MR treating versus OBS 
      mainly in the poor-risk cohort. PFS at 10 years reached 57.1 versus 22.7 % (P < 
      0.01), and 10-year OS was 71.2 versus 41.7 % (P < 0.01). Compared with OBS, no 
      severe hematologic adverse events (AEs) (Grades 3-4) appeared in patients with 
      MR; only some mild non-hematologic AEs incurred (nausea-vomiting 0.96 %, allergy 
      1.9 % and infection 1.9 %) during the maintenance treatment. The study showed 
      that MR improved 10-year RFS and OS for cytogenetic poor-risk patients with CLL.
FAU - Huang, Bin-Tao
AU  - Huang BT
AD  - Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical 
      University, 1 TongDao Avenue North, Hohhot, 010059, People's Republic of China, 
      huangbintao1979@sina.com.
FAU - Zeng, Qing-Chun
AU  - Zeng QC
FAU - Zhao, Wei-Hong
AU  - Zhao WH
FAU - Li, Bing-Sheng
AU  - Li BS
FAU - Chen, Rui-lin
AU  - Chen RL
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140702
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage/*adverse 
      effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Cyclophosphamide/administration & dosage
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy/*genetics/mortality
MH  - Male
MH  - Prospective Studies
MH  - Risk Factors
MH  - Rituximab
MH  - Treatment Outcome
MH  - Vidarabine/administration & dosage/analogs & derivatives
EDAT- 2014/07/06 06:00
MHDA- 2015/05/15 06:00
CRDT- 2014/07/03 06:00
PHST- 2014/05/22 00:00 [received]
PHST- 2014/06/23 00:00 [accepted]
PHST- 2014/07/03 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
AID - 10.1007/s12032-014-0104-7 [doi]
PST - ppublish
SO  - Med Oncol. 2014 Aug;31(8):104. doi: 10.1007/s12032-014-0104-7. Epub 2014 Jul 2.